As part of our ongoing aim to bring you reports of interesting new studies, we have added a review of a 3-year study of baricitinib efficacy in moderate-to-severe rheumatoid arthritis.
Independent expert commentary is provided by Associate Professor Andrew Ostor consultant rheumatologist at Cabrini Medical Centre.
Please login below to download this issue (PDF)